Johnson & Johnson’s prostate cancer drug shrinks tumors in early-stage trial
Summary
An early-stage clinical trial evaluating a Johnson & Johnson prostate cancer medication showed that the treatment successfully reduced tumor sizes. According to the preliminary testing results, the pharmaceutical company observed a decrease in the size of cancerous growths from the therapy.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.